Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) announced that David Zaccardelli, Pharm. D., the CEO, will present an overview of the company at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand from 7:00 AM EST / 12:00 PM GMT on January 10, 2022. Interested parties can access a webcast of the event for 90 days via the company's website's Investors page. Verona Pharma focuses on developing innovative therapies for respiratory diseases, with its product candidate ensifentrine currently in Phase 3 development for COPD.

LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand starting at 7:00 AM EST / 12:00 PM GMT on Monday, January 10, 2022.

A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc	US Tel: +1-833-417-0262 UK Tel: +44 (0)203 283 4200
Victoria Stewart, Director of Investor Relations and Communications	info@veronapharma.com
Argot Partners (US Investor Enquiries)	Tel: +1-212-600-1902 verona@argotpartners.com
Kimberly Minarovich / Michael Barron
Optimum Strategic Communications (International Media and European Investor Enquiries)	Tel: +44 (0)203 950 9144 verona@optimumcomms.com
Mary Clark / Stella Lempidaki / Zoe Bolt

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com. 

FAQ

What is the date of the Verona Pharma presentation at the H.C. Wainwright BioConnect Virtual Conference?

The presentation is scheduled for January 10, 2022.

Who will present at the H.C. Wainwright BioConnect Virtual Conference for Verona Pharma?

David Zaccardelli, Pharm. D., the President and CEO, will present.

How can I access the Verona Pharma presentation?

The presentation will be available on-demand starting at 7:00 AM EST on January 10, 2022.

What is ensifentrine being developed for?

Ensifentrine is being developed as a treatment for COPD and other respiratory diseases.

Where can I find the webcast of the Verona Pharma event?

The webcast will be available on the Investors page of Verona Pharma's website for 90 days.